Boston Scientific Comments On Positive Results With The FLEX(TM) Microwave Ablation System

Boston Scientific
Corporation (NYSE: BSX) today commented on data released on May 9th at the
American Association for Thoracic Surgery (AATS) conference in Washington,
D.C. Dudley A. Hudspeth, M.D., of Desert Cardiothoracic Surgeons in Mesa,
Arizona, reported positive results from his single-center clinical
investigation of 79 patients treated with the FLEX 10(R) and FLEX 10(R) XE
Microwave Ablation Probes. Patients in the study achieved greater than 95
percent conversion to sinus rhythm based on electrocardiograms and 30-day
event monitoring. Significantly, 82 percent of patients at one-year
follow-up were off anti-arrhythmic medications and 68 percent of patients
at one-year follow-up were off anti-coagulant medications.



Following the presentation, Dr. Hudspeth stated, "Standard medical
therapy often fails to treat AF patients' symptoms. These data look
promising for a minimally invasive ablation procedure for appropriate AF
patients." Most procedures in the series were performed through a few small
incisions (